Biomedicines (Apr 2023)

Somatic Copy Number Alteration in Circulating Tumor DNA for Monitoring of Pediatric Patients with Cancer

  • Juliana Silveira Ruas,
  • Felipe Luz Torres Silva,
  • Mayara Ferreira Euzébio,
  • Tássia Oliveira Biazon,
  • Camila Maia Martin Daiggi,
  • Daniel Nava,
  • Mayra Troiani Franco,
  • Izilda Aparecida Cardinalli,
  • Alejandro Enzo Cassone,
  • Luiz Henrique Pereira,
  • Ana Luiza Seidinger,
  • Mariana Maschietto,
  • Patricia Yoshioka Jotta

DOI
https://doi.org/10.3390/biomedicines11041082
Journal volume & issue
Vol. 11, no. 4
p. 1082

Abstract

Read online

Pediatric tumors share few recurrent mutations and are instead characterized by copy number alterations (CNAs). The cell-free DNA (cfDNA) is a prominent source for the detection of cancer-specific biomarkers in plasma. We profiled CNAs in the tumor tissues for further evaluation of alterations in 1q, MYCN and 17p in the circulating tumor DNA (ctDNA) in the peripheral blood at diagnosis and follow-up using digital PCR. We report that among the different kinds of tumors (neuroblastoma, Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, leiomyosarcoma, osteosarcoma and benign teratoma), neuroblastoma presented the greatest amount of cfDNA, in correlation with tumor volume. Considering all tumors, cfDNA levels correlated with tumor stage, metastasis at diagnosis and metastasis developed during therapy. In the tumor tissue, at least one CNA (at CRABP2, TP53, surrogate markers for 1q and 17p, respectively, and MYCN) was observed in 89% of patients. At diagnosis, CNAs levels were concordant between tumor and ctDNA in 56% of the cases, and for the remaining 44%, 91.4% of the CNAs were present only in cfDNA and 8.6% only in the tumor. Within the cfDNA, we observed that 46% and 23% of the patients had MYCN and 1q gain, respectively. The use of specific CNAs as targets for liquid biopsy in pediatric patients with cancer can improve diagnosis and should be considered for monitoring of the disease response.

Keywords